Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | CD274 over exp STK11 A205Rfs*82 |
Therapy | Pembrolizumab |
Indication/Tumor Type | lung squamous cell carcinoma |
Response Type | predicted - resistant |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
CD274 over exp STK11 A205Rfs*82 | lung squamous cell carcinoma | predicted - resistant | Pembrolizumab | Case Reports/Case Series | Actionable | In a clinical case study, a lung squamous cell carcinoma patient with high CD274 (PD-L1) expression progressed after initial response to Keytruda (pembrolizumab) and through subsequent ctDNA testing was found to have acquired STK11 A205Rfs*82 (PMID: 33832284). | 33832284 |
PubMed Id | Reference Title | Details |
---|---|---|
(33832284) | The influence of STK11 mutation on acquired resistance to immunotherapy in advanced non-small cell lung cancer with Lynch syndrome: a case report and literature review. | Full reference... |